Form 4: NAMS Chief Accounting Officer Sells Shares

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, sold ordinary shares after exercising stock options.

Summary

• Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NAMS), reported transactions involving the company's ordinary shares.
• On January 27, 2026, Kooij acquired 39,816 ordinary shares by exercising options at a price of $10.9 per share.
• Immediately following the option exercise on January 27, 2026, Kooij sold 39,816 ordinary shares at a weighted average price of $32.62 per share, with individual sales ranging from $32.29 to $32.97.
• On January 28, 2026, Kooij acquired an additional 32,612 ordinary shares by exercising options at a price of $10.9 per share.
• Following this exercise on January 28, 2026, Kooij sold 32,612 ordinary shares at a weighted average price of $31.8 per share, with individual sales ranging from $31.58 to $32.53.
• After these transactions, Kooij directly beneficially owns 24,353 ordinary shares.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• The options exercised were granted on January 1, 2023, with 25% vesting on the one-year anniversary of the vesting start date and the remainder vesting in equal monthly installments over three years, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents a routine insider transaction involving the exercise of stock options and subsequent sale of shares, likely for personal financial planning, and does not provide new material information about the company's operational or financial health.

Positives

• The Chief Accounting Officer realized a significant profit from exercising stock options and selling shares, indicating personal financial benefit from the company's stock performance.
• The transactions were conducted under a Rule 10b5-1(c) plan, suggesting a pre-scheduled and pre-arranged sale, which can reduce concerns about opportunistic insider trading.

Negatives

• An insider, specifically the Chief Accounting Officer, sold a substantial number of shares, which some investors might interpret as a lack of confidence, although it is often a routine event for option exercises.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the exercise of stock options followed by a sale of shares, are common occurrences in publicly traded companies. When executed under a Rule 10b5-1 plan, these sales are typically pre-arranged and often relate to personal financial planning, tax obligations, or portfolio diversification rather than a change in the insider's view of the company's prospects. Such routine transactions are generally viewed as less impactful than unscheduled, large-scale insider selling.

Comparison to Industry Standards

• This Form 4 reports an individual insider's stock transactions and does not provide company-level financial or operational results that can be directly compared to industry benchmarks or competitor performance.
• The practice of executives exercising stock options and selling shares, often referred to as 'cashless exercise' or 'sell-to-cover,' is a standard compensation mechanism across various industries, including the pharmaceutical sector where NewAmsterdam Pharma operates.

Stakeholder Impact

• Shareholders: May observe insider selling, but the Rule 10b5-1 plan context suggests it's a pre-planned, routine event, likely mitigating negative sentiment. The officer realized a profit, which can be seen as a positive outcome of the company's stock performance.

Next Steps

• The remaining unexercised options held by Louise Kooij will continue to vest in equal monthly installments for three years following the one-year anniversary of the vesting start date, subject to her continued service.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares, likely for tax purposes or portfolio diversification. It does not provide new fundamental information about the company's operations or financial health to warrant a change in investment recommendation. Investors should continue to evaluate NewAmsterdam Pharma based on its core business performance and strategic outlook.

Keywords

NewAmsterdam Pharma, NAMS, Insider Trading, Form 4, Stock Options, Share Sale, Louise Kooij, Chief Accounting Officer, Rule 10b5-1